Subject(s)
COVID-19/therapy , Respiration, Artificial , Academic Medical Centers , Aged , Aged, 80 and over , COVID-19/physiopathology , Continuous Positive Airway Pressure , Critical Illness , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , New York City , Pilot Projects , Retrospective Studies , Treatment OutcomeABSTRACT
Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome is characterised by fever, rash, eosinophilia and organ damage that develops 2-6â weeks after the initiation of a medication. We report a case of DRESS syndrome in a 79-year-old man that developed after the introduction of rifabutin, ethambutol and clarithromycin used to treat Mycobacterium avium complex (MAC) vertebral osteomyelitis. This case highlights treatment and management challenges in a patient with known MAC vertebral osteomyelitis requiring prolonged steroids. Steroids are the mainstays of treatment for moderate to severe cases of DRESS syndrome. Initiation of steroids for the treatment of DRESS syndrome among patients with concomitant infections requires multidisciplinary collaboration for optimal management.
